KD 406
Alternative Names: KD-406Latest Information Update: 28 Jul 2023
At a glance
- Originator KM Biologics
- Class Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Zika-virus-infection(Prevention) in Japan (IM)
- 31 Mar 2020 KM Biologics completes a phase I trial in Zika virus infection (Prevention) in Japan (IM) in March 2020 (JapicCTI194772)
- 21 Jun 2019 Phase-I clinical trials in Zika virus infection (Prevention) in Japan (IM) in June 2019 (JapicCTI194772)